Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.
The relationship between outer retinal integrity, subretinal fluid may affect treatment outcomes
Dr Justis Ehlers presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.
Delving into the 24-week results for UBX1325 for the treatment of chronic DMO, wet AMD
Dr Raj K. Maturi presented a talk entitled, “UBX1325, A Novel Senolytic Therapy for Treatment- Experienced Patients With Chronic DMO or Wet AMD: 24-Week Results of a Phase 1 Study.”
TRUCKEE study: Real-world safety and efficacy of faricimab for neovascular AMD
Dr Carl Danzig, and colleagues reported that treatment with faricimab (Vabysmo, Roche) in patients with neovascular age-related macular degeneration (AMD) achieved improvements in the visual acuity (VA), central subfield thickness (CST), and pigment epithelial detachments (PEDs).
This is encouraging because the ongoing TRUCKEE study population is comprised of patients who require frequent injections to address persistent disease activity associated with neovascular AMD.
The investigators analyzed the patient demographic data, the previous treatment history, efficacy, and safety of patients treatment with faricimab who had in most cases been treated with another drug for neovascular AMD.
The patients were about a mean of 80 years of age and had been treated previously with aflibercept (Eylea, Regeneron Pharmaceuticals) in more than half of cases, followed by ranibizumab (Lucentis, Genentech), and brolucizumab (Beovu, Novartis). About 15% were treatment naïve. In most cases aflibercept was the last previous treatment.
DMO: Faricimab remains durable, effective in 2-year results of YOSEMITE and RHINE trials
Dr David Eichenbaum presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Oedema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”
Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuity
Dr Yoshihiro Yonekawa from the Wills Eye Hospital, Mid Atlantic Retina, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, and colleagues took a look at retinal detachments in pediatric patients to get a broad view on the status of treatment on a national level.
The goals of this multicenter cohort study were to determine the demographics of retinal detachment in children in the US and report the treatment modalities and visual outcomes, according to Dr Yonekawa.
The investigators examined the aggregated electronic health records of all identified children who ranged in age from 1 to 17 years between January 2015 and August 2021 in a national database. All children had a rhegmatogenous retinal detachment (RRD) based on the ICD10 and CPT codes. The investigators then analyzed the demographic data, comorbidities, visual acuity (VA) levels, and treatment modalities.
PEACHTREE post hoc analysis: Significant reduction of macular edema, low rate of rescue in patients with chronic uveitis
Dr Christopher Henry presented a talk entitled, “Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Oedema in Patients With Chronic Uveitis.”